errors of human metabol~sm spec~fic to L-~soleuc~ne degradatton. EA presented at three days of age with lethargy, hypoglycemia and apnea. M R I demonstrated ischemic changes bilaterally In par~etal and occ~pttal lobes and abnormal EEG Acylcarnit~nes in plasma were increased (range 8-22 uM, n=7; nl. 3-10) , Tandem mass spectrometry (MSIMS) analysis revealed elevated plasma C,-acylcarn~t~ne (1 4-2.4 p M , nl < 0.4), verified as 2-methylbutyrylcarnitine by gas chromatography-mass spectromeuy Urine 2-methylbutyrylglyc~ne (2-MBG) was consistently elevated (range 8-30 mdgcreatinlne. n=6, nl < 8). Intact fibroblast convers~on of U-"C-~solcuc~ne to "CO, was decreased to 26% of control. comparable to that of BKT deficient f~brohlasts Convers~on of "C,-leuc~ne and "C,-valine in patlent's fibroblasts Incubated w~t h L-carnit~ne revealed no abnormal accumulation of acylcarn~tines. In the same cells. there was a 10-fold accumulat~on of C,-acylcarnltlne incompanson tocontrol (consistent wlth lmpalred 2-MBCDase activ~ty) when Incubated w~t h "C,-~soleuc~ne and L-cam~t~ne Western-blot analys~s of fibroblasts from E A revealed greatly reduced 2-MBCDase cross-reactlve mdter~al Mutation screening In pauent fibroblasts revealed a C778T subst~tut~on In the 2-MBCDase gene, substttutlng leuc~ne for phenylalan~ne at amlno ac~d 222 IL???F), the patlent's mother alro carried th~s mutauon. I n a subsequent pregnancy. the concentratlon of 2-MBG In amnlotlc fluid obta~nedat 15 weeks geitauon was0 27 umollLlnl <O 04, n=S). wh~le total C,-acylcarn~ttne concentratlon was 1.9 umollL In1 < 0 7. n=27), suggesung an affected fetus Cultured amnlocytes accumulated excess (10-fold) C,-acylcarn~t~ne when ~ncuhated w~t h "C,-tsoleuc~ne and L-carnltlne At I year of ape EA carrles the dlagnos~s of athctoid cerebral palsy. and continues to man~fest ~mpalred v~sual. motor and cognlllve sk~lls. Our stud~cs revcal I ) the first documented case of Isolated 2-MBCDnsc deficlcncy. 2) a novel mutJlton
In the 2-MBCDase gene; and 3) the f~rst prenatal d~apnos~s of an affected fetus w~t h 2- We report 2 affected slbs w~t h typical cl~nical and b~ochemlcal phenotypes, and braln MRI findings. Patlent I 18 a 5 years old glrl who presents w~t h developmental delay, spastic quadr~pleg~a, and chronlc diarrhea. She was hosp~tal~red several t~mes due to chron~c diarrhea and pneumonla In the early infancy. She developed frequent skin petech~ae on compression sites and cyanosls on the lower extremltles Brain MRI taken at the age o f 25 months was suggestive o f hypovlc ~schem~c encepahlopathy and no further evaluat~on was undertaken Patlent 2 . her younger sister, 18 a 34 months old girl who presents wlth a slmllar cllnlcal course but had no evaluation u n t~l recently when she developed respiratory d~fficulty due to pneumonla which requlred hosp~tal~zation. She was able to control her head at 4 months of age and crawl at 9 months of age but never s~t, stand or talk. Her spastlc quadr~plegia became worse after th~s eplsode and she IS almost wheel chair hound Brain MRI showed multlfocal nodular T2 hlgh signals In both basal ganglla w~t h enhancement. patchy 1-2 high stgnals In both periventricular whtte matter. ccntrum sem~ovale, and cerebellum. Muscle blopsy showed diffuse atrophy but no evidence of mltochondrial disorder Organlc acid and acylglycine profiles showed markedly ~l~v a t e d excretton of ethvlmalonic ac~d (134 mmol/mol creatlnine. controls: < I 8).
-. . -. . -~\obur)r, Iglyclne. but)^ Igl)c~ne. mcth) I b u t )~ Igl!c~nc. and ~~ovalerylgl)clne mere nl,n elebated Serum 13ct;1rr. wd, 3 ? mmul I. tcontrol 0 7-2 01 100 mg Lg da) oral ~ camitine supplementatton for 2 months had no vislble effect. However. they became significantly more active and alert on r~boflavin treatment (100 mdday) Patient I rolled over and was soc~ally more active with laughlng and sounds. In patient 2, motor improvement was not slgn~ficant but she became more alen and socially active. Notably, the chron~c rnucold diarrhea substded cons~derably in both children, but petechiae were unaffected Our observat~ons suggest that some cases with ethylmalonic encephalopathy could be respons~ve to nboflavin. In vltro evaluat~on of fatty acid and branched chain amino ac~d metabol~sm is in progress. RCDP was initially diagnosed in a newborn female who had typical symmetric rhizomelic shortening of the extremities, ~netaphyseal changes, multiple punctate skeletal calcifications. icthyosis, bilateral cataracts and Koala bear facies. The patient succumbed at 12 weeks of age. Diagnostic evaluations were u~evealing, including normal peroxisomal very long chain fany acids. phytanic acid hydrolase and plasmalogen biosynthesis. Fibroblasts where reanalyzed for defects in 3-beta-hydroxysteroid-A(8), A(7)-isomerase, which was recently identified to cause X-linked Co~adi-Hiinermann Syndrome. G C N S analysis revealed a panem of metabolites consistent with this enzymatic defect in cholesterol biosynthesis, specifically showing increased levels of 8-dehydrocholesterol and 8(9)-cholesterol. Genomic DNA was isolated from the patient's fibroblasts and the gene for 3-beta-hydroxysteroid-A(8). A(7)-isomerase (EBP, located at Xp11.2) was sequenced (all exons and intronic junctions). Results showed 3 mutations in cis in exon 2 : L42X (125T>A), W47X (140G>A) and L49L (147G>A)(a synonymous change). The other allele showed a wild type sequence. The EBP gene were sequenced in blood lymphocytes from both parents and were normal.
This case highlights the heterogeneity of CDPX2. The range of he no typic severity seen in this disorder is presumably due to variable lyonization. We show that severe CDPX2 is a phenocopy of peroxisomal RCDP. We have also identified a novel mutation that could have originated from a pseudogene or another unknown mechanism.
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